{
    "cancer_info": {
        "cancer_name": "Cutaneous Squamous Cell Carcinoma"
    },
    "diagnosis_recommendations": {
        "examinations": [
            "Full-body skin examination",
            "Lymph node palpation",
            "Punch biopsy (including deep reticular dermis)",
            "Shave biopsy",
            "Excisional biopsy",
            "MRI with contrast (for perineural disease or deep soft tissue involvement)",
            "CT with contrast (for bone invasion assessment)",
            "FDG-PET/CT (for distant metastasis evaluation)",
            "Ultrasound (regional lymph node assessment)",
            "Fine Needle Aspiration (FNA)/Core Biopsy (for suspicious lymph nodes)",
            "Sentinel Lymph Node Biopsy (SLNB) for high/very high-risk cases",
            "Pathology reporting (margin status, differentiation, depth, perineural/lymphovascular invasion, histologic subtype)"
        ]
    },
    "staging_treatment_plans": [
        {
            "staging_criteria": "Field Cancerization/Confluent Epidermal Dysplasia",
            "risk_group": "Precursor lesions",
            "treatment_plans": [
                {
                    "treatment_line": "Prevention",
                    "patient_subgroup": "All patients",
                    "plan_name": "Sunscreen and nicotinamide",
                    "plan_details": "Daily sunscreen; Oral nicotinamide 500mg BID to reduce new cSCC",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred prevention"
                },
                {
                    "treatment_line": "Primary",
                    "patient_subgroup": "Actinic keratosis",
                    "plan_name": "Topical therapy",
                    "plan_details": "Topical 5-fluorouracil/calcipotriol, imiquimod, or photodynamic therapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Low Risk",
            "risk_group": "Low Risk",
            "treatment_plans": [
                {
                    "treatment_line": "Primary",
                    "patient_subgroup": "Localized tumors",
                    "plan_name": "Surgical excision",
                    "plan_details": "4-6mm margins; Mohs micrographic surgery (MMS) or curettage/electrodessication (C&E)",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Adjuvant",
                    "patient_subgroup": "Positive margins",
                    "plan_name": "Re-excision",
                    "plan_details": "Surgical re-excision for margin clearance",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "High/Very High Risk",
            "risk_group": "High/Very High Risk",
            "treatment_plans": [
                {
                    "treatment_line": "Primary",
                    "patient_subgroup": "Resectable tumors",
                    "plan_name": "Mohs surgery",
                    "plan_details": "Peripheral/deep en face margin assessment (PDEMA)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Adjuvant",
                    "patient_subgroup": "PNI+, positive margins, or extensive nerve involvement",
                    "plan_name": "Radiation Therapy",
                    "plan_details": "50-60 Gy adjuvant radiation",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Neoadjuvant",
                    "patient_subgroup": "Borderline-resectable tumors",
                    "plan_name": "Cemiplimab",
                    "plan_details": "Anti-PD-1 inhibitor prior to surgery",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Locally Advanced/Unresectable",
            "risk_group": "Advanced disease",
            "treatment_plans": [
                {
                    "treatment_line": "Primary",
                    "patient_subgroup": "Unresectable tumors",
                    "plan_name": "Cemiplimab + RT",
                    "plan_details": "Neoadjuvant cemiplimab ± radiation therapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Systemic therapy",
                    "patient_subgroup": "Ineligible for immunotherapy",
                    "plan_name": "Carboplatin/Paclitaxel",
                    "plan_details": "Chemotherapy regimen",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other Recommended"
                }
            ]
        },
        {
            "staging_criteria": "Regional Lymph Node Involvement",
            "risk_group": "Node-positive",
            "treatment_plans": [
                {
                    "treatment_line": "Primary",
                    "patient_subgroup": "Resectable nodes",
                    "plan_name": "Neck dissection",
                    "plan_details": "Parotidectomy + neck dissection",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "Adjuvant",
                    "patient_subgroup": "ENE+, multiple nodes",
                    "plan_name": "Chemoradiotherapy",
                    "plan_details": "Cisplatin 100mg/m² q3w + RT (60-66 Gy)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                }
            ]
        },
        {
            "staging_criteria": "Metastatic Disease",
            "risk_group": "Distant metastasis",
            "treatment_plans": [
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "All eligible patients",
                    "plan_name": "Cemiplimab/Pembrolizumab",
                    "plan_details": "Anti-PD-1 inhibitors (ORR 44-50%)",
                    "nccn_evidence_category": "Category 1",
                    "nccn_recommendation_category": "Preferred"
                },
                {
                    "treatment_line": "First-line",
                    "patient_subgroup": "Checkpoint-ineligible",
                    "plan_name": "Carboplatin/Paclitaxel",
                    "plan_details": "Chemotherapy regimen",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other Recommended"
                },
                {
                    "treatment_line": "Targeted therapy",
                    "patient_subgroup": "EGFR overexpression",
                    "plan_name": "Cetuximab",
                    "plan_details": "EGFR inhibitor monotherapy",
                    "nccn_evidence_category": "Category 2A",
                    "nccn_recommendation_category": "Other Recommended"
                }
            ]
        }
    ],
    "biomarker_clinical_significance": {
        "clinical_significance": [
            "Perineural Invasion (PNI) predicts 2.5× increased recurrence risk and nodal metastasis; requires adjuvant RT",
            "Lymphovascular Invasion (LVI) indicates high risk for nodal metastasis",
            "Tumor depth >6mm correlates with nodal metastasis and poor prognosis",
            "Desmoplastic, adenosquamous, and acantholytic histologic subtypes are associated with aggressive behavior",
            "PD-L1 expression predicts response to anti-PD-1 inhibitors (cemiplimab/pembrolizumab)",
            "Immunosuppression (e.g., transplant recipients) increases cSCC risk 65-250× and worsens prognosis",
            "Extranodal spread ≥1mm indicates need for adjuvant chemoradiation",
            "DNA repair defects (XP genes) increase susceptibility to UV-induced carcinogenesis"
        ]
    },
    "guideline_id": "（2025.V2）NCCN临床实践指南：皮肤鳞状细胞癌.txt"
}